Skip to content

Additional electroconvulsive therapy and acupuncture for hospitalized patients with schizophrenia: a retrospective controlled study

Additional electroconvulsive therapy and acupuncture for hospitalized patients with schizophrenia: a retrospective controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR1900002377
Enrollment
Unknown
Registered
2019-06-02
Start date
2019-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Sponsors

Xi'an Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) either gender aged 18-75 years; (2) was hospitalized for schizophrenia as the principal diagnosis according to the International Classification of Diseases (10th version) (ICD-10); (3) had olanzapine- or risperidone-containing treatment combined with or without ACP or/and ECT during their stay in the hospital; (4) had complete medical record and full clinical assessment.

Exclusion criteria

Exclusion criteria: (1) other non-pharmacological treatment in addition to ACP and ECT during hospitalization; (2) had ACP treatment for one week or more at admission to hospital; (3) a history of brain tumors or intracranial space-occupying lesions; (4) a history of alcohol or substance abuse within the previous one year; (5) an investigational treatment within the previous one year.

Design outcomes

Primary

MeasureTime frame
Scale for the Assessment of Positive Symptoms (SAPS);Scale for the Assessment of Negative Symptoms (SANS);

Secondary

MeasureTime frame
Body weight;Treatment Emergent Symptom Scale (TESS);

Countries

China

Contacts

Public ContactZhang Zhangjin

School of Chinese Medicine, The University of Hong Kong

zhangzj@hku.hk+852 39176445

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026